Advances in Pediatric Acute Lymphoblastic Leukemia Treatment
نویسندگان
چکیده
منابع مشابه
Treatment of Pediatric Acute Lymphoblastic Leukemia and Recent Advances
Pediatric acute lymphoblastic leukemia (ALL) is the most prevalent cancer in children. Today in developed countries around 80% of children with ALL can achieve 10 year survival. This great improvement in treatment outcomes for pediatric ALL is due to several important advances which have taken place since the 1960s, including intensive induction/consolidation chemotherapy regimens, risk-adapted...
متن کاملUBE2Q1, as Down Regulated Gene in Pediatric Acute Lymphoblastic Leukemia
Ubiquitin - proteasome system (UPS), the major protein degradation pathway in the cells, typically degrades short - lived and damaged proteins and regulates growth and stress responses. This pathway is altered in various cancers, including Acute Lymphoblastic Leukemia (ALL). ALL begins with a change in bone marrow cells and is the most common type of leukemia in children under 15 years. UBE2Q1...
متن کاملRecent advances in the management of pediatric acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) is the most common malignancy in childhood. Despite enormous improvement of prognosis during the last half century, ALL remains a major cause of childhood cancer-related mortality. During the past decade, whole genomic methods have enhanced our knowledge of disease biology. Stratification of therapy according to early treatment response measured by minimal res...
متن کاملTreatment of pediatric acute lymphoblastic leukemia.
Acute lymphoblastic leukemia (ALL) is the most common pediatric oncologic diagnosis, and advances in its treatment have led to progressive improvements in survival. The 4 main components of therapy are remission induction, consolidation, maintenance, and central nervous system-directed therapy, and usually last 2 to 3 years. Treatment intensity based on risk-based stratification is the cornerst...
متن کاملPediatric Acute Lymphoblastic Leukemia
Results ETV6/RUNX1 had a strong effect on overall survival after relapse (3-year survival= 64.7% for positive cases versus 46.5% for negative cases) (P=0.007). The 5-year cumulative incidence of relapse was 19.4% and testes were more frequently involved in ETV6/RUNX1-positive relapses (P=0.04). In 81.4% of cases the relapses were late, early combined or isolated extramedullary relapses. The 5-y...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncology Times
سال: 2020
ISSN: 0276-2234
DOI: 10.1097/01.cot.0000725472.26939.d9